Faster healing and lower cost of care
Aspiera was founded in 2013 and is dedicated to providing nurses and doctors with the highest quality non-prescription topical medications for prevention and treatment of skin infections, wounds and pain.
Our US-made formulations combine the purest natural and pharmaceutical ingredients with our patented Positively-Charged-Targeting™ technology to produce extraordinarily-effective healthcare solutions. Our brand is called Fastrin™ because our products work much faster to resolve skin infections, heal wounds and reduce musculoskeletal pain–thus reducing the cost of care.
Fastrin products are distributed to Skilled Nursing Facilities, Home Healthcare Providers, Hospitals, Wound Care Centers and Specialty Physicians.
Our pipeline products include a topical prescription medication for the treatment of rare skin disorders, including epidermolysis bullosa.
We sincerely enjoy collaboration with physicians and researchers. The folks at Aspiera Medical are collaborators in good science, improved patient healing, and smart business. We’d love to talk with you about all of this and explore new ways to deliver high-value to your practice and your patients.
Co-Founder & Managing Director
David Goldsmith serves as Managing Director of Aspiera Medical. He is also co-founder and Board member of Aidance Scientific. David earned a Bachelor of Science degree in Environmental Science then joined the research staff at Brown University where he produced original published research. At the age of 29 he launched his first company, which achieved international sales within six months. He went on to build a successful business consulting practice, integrating business development strategy, organizational assessment, and infrastructure-development for major corporations, universities, high-tech and zero-early stage companies. In 2003 David helped launched Aidance and was involved in all facets of the business. With the 2013 formation of Aspiera Medical, David’s current role is focused on business development for the Fastrin product line and the pathway towards regulatory approval in the US and Europe for a topical drug treating rare wounds and skin disorders. David is supported by a team of people involved in research, product development, manufacturing, quality systems, and other key areas.
Ms. Osborne is President and CEO at LEO Pharma Inc., where she is responsible for management of the LEO U.S. Leadership Team comprised of the sales, marketing, medical strategy & scientific affairs, legal & compliance, finance, and human resources functions at LEO U.S. In her position, Ms. Osborne also serves on the LEO Pharma Global Management Team (GMT) and the global LEO Top Leadership Team (LTLT). Prior to joining LEO U.S., Ms. Osborne served as President of Mölnlycke Health Care’s U.S. Wound Care Division. Mölnlycke is a 1 Billion Euro global manufacturer and marketer of advanced wound care dressings and operating room supplies. Before her role as president, Ms. Osborne held the position as Vice President of Sales at Mölnlycke when she joined the organization in 2007. Ms. Osborne’s background includes over 27 years of experience in the healthcare industry. Prior to Mölnlycke, she held positions at C.R. Bard as Director of Marketing, Microtek Medical Holdings Inc. as Executive Vice President of Sales & Marketing, and Covidien/Kendall-LTP as Vice President & General Manager.
Tanya Rhodes, PhD
Tanya Rhodes, PhD, is President and CEO of Rhodes & Associates, a consulting firm founded in 2004 that provides strategic business consulting services from concept through commercialization. She has held President and General Management positions in both the Professional and Retail market sectors of wound care bringing forward new innovations and drug device combinations from concept to commercialization. Earlier in her career, Dr. Rhodes was Vice President of Innovation for Smith & Nephew both in the US and UK. During her tenure, Smith and Nephew US grew from $27 million to over $150 million. Dr. Rhodes holds a Masters Degree with a major in Technology Management from the University of Miami and graduated with honors in Chemistry from Hull University, England, as well as completing research for her PhD in Computational Stereochemistry before relocating to the US.
Jeffrey A. Niezgoda, MD, FACHM, FAPWCA, CHWS
President of the American College of Hyperbaric Medicine and an Associate Professor and Hyperbaric Consultant at the Medical College of Wisconsin in Milwaukee. Dr. Niezgoda is a recognized wound care expert and has served as faculty at both national as well as international conferences. He has participated on multiple Expert Consensus Panels and has appeared before Medicare and Medicaid Services as a wound care advisor. He is founder and President of WebCME, a multifaceted company that offers continuing medical education via an advanced online interface. Dr. Niezgoda is also the President and Chief Operating Officer of Hyperbaric & Wound Care Associates, a medical specialty group serving Southeastern Wisconsin and Northern Illinois. He is the former Medical Director of The Centers for Comprehensive Wound Care and Hyperbaric Oxygen Therapy, St. Luke’s Medical Center, Aurora Health Care, in Milwaukee, Wisconsin. Dr. Niezgoda received his Medical Degree from the Uniformed Services University of the Health Sciences, F. Edward Hebert School of Medicine, Bethesda, Maryland, and earned a Bachelor of Science in Biology from U.S. Air Force Academy, Colorado Springs, Colorado. Dr. Niezgoda is Board Certified in Hyperbaric Medicine and Wound Care.
Brock Liden, DPM
Columbus Ohio-area podiatrist who is actively engaged in clinical and product research. In addition to managing two podiatry offices, Dr. Liden is co-medical director of Berger Hospitals Wound Healing Center with Hyperbaric Oxygen Therapy. He received his degree from the Ohio College of Podiatric Medicine and served his residency at the Veterans Medical Center in Cleveland, Ohio.
Gianni Belcaro, MD, PhD
Dr. Belcaro is Director of the Irvine3 Vascular Laboratory and Professor of Angiology in the Cardiology School at Chieti University, Pescara, Italy. He has authored or co-authored more than 400 scientific articles and original papers, and more than 24 books. He has presented research and chaired sessions at more than 300 national and international meetings. Dr. Belcaro is a member of the editorial boards for several journals, including Angiology, Angeiologie, Journal of Cardiovascular Surgery, International Angiology, Clinical and Applied Thrombosis and Hemostasis, and Minerva Cardio-Angiologica.